07 jun: USA/tendens: Kina og Spanien ventes at give stigninger
07 jun: Carlsberg: Ølsalget firedobles før EM-kamp
07-06-2012 14:57:00

PRESS RELEASE: Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Powerful New Certegra(R) Informatics Workstation launched at SIIM 2012

Intended for U.S. Media Only

PR Newswire

TARRYTOWN, N.Y., June 7, 2012

TARRYTOWN, N.Y., June 7, 2012 /PRNewswire/ -- Bayer Radiology & Interventional announced the introduction of the Certegra(R) Workstation, an informatics-driven, touch--screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management(TM) applications and a new P3T(R) 2.0 operating environment. The new Workstation will be presented at the annual meeting of the Society for Imaging Informatics in Medicine (SIIM) 2012 June 7 - 12 in Orlando, FL. Following the initial launch in the U.S. and Canada, the Workstation will be rolled out in phases in markets around the world.

The Workstation serves as a single interface for radiology technologists, enabling them to provide improved patient care from study set-up and preparation to administration of the patient's study. It will be the cornerstone of Bayer's industry-first[1] Contrast Dose Management solution and informatics platform. In establishing and uploading the patient's contrast-injection record, the Workstation imports patient data directly from the Modality Work List -- reducing manual entry errors to the patient record.

"Today's technology-driven CT suite demands timely access to reliable contrast-dose records throughout the chain of care," said Anthony Cinalli, vice president of the informatics business at Bayer Radiology & Interventional. "Enabling a single workflow-centralized interface, the Workstation allows for fewer clicks, less manual entry and greater control over the quality and consistency of patient care."

Interfacing with Medrad Stellant(R) CT injection systems, the Workstation's comprehensive suite of software options provides physicians and healthcare professionals instant access to real-time actionable CT contrast data captured at the point of care enabling benefits including:

-- Reduce sub-diagnostic studies, unnecessary rescans and associated

radiation exposure[2] [3],(P3T 2.0 for personalized CT abdominal, cardiac

and pulmonary angiography studies)

-- Enable more complete diagnostic decisions (PACS Outbound Interface)

-- Speed-up radiology report turnaround time and create greater study-volume

bandwidth (RIS and SR Outbound Interfaces)

-- Improve department performance by trending, reporting and analyzing

actionable data with pinpoint accuracy (Informatics Starter Package, and

the Data Analysis and Reporting Tool)

Bayer HealthCare will have the Certegra(R) Workstation on display at its booth at SIIM 2012 (booth #217 - 221).

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

[1] Reference on file.

[2] Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible, MD, PhD. Study supported by MEDRAD Inc.

[3] 510(k) FDA clearance number: K082905

SOURCE Bayer HealthCare

/CONTACT: Karen Sutherland, +1-973-487-2113, karen.sutherland@bayer.com or Alicia Cafardi, +1-724-940-8621, alicia.cafardi@bayer.com

/Web site: http://www.bayerhealthcare.com/

(END) Dow Jones Newswires

June 07, 2012 08:57 ET (12:57 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 apr
OMXC20
  Advarsel!   Dette indlæg er ikke for aktieanalytikere, der hæver deres kurstarget hver gang kursen..
65
24 apr
 
Jeg er kommet i besiddelse af EU’s harmoniseringsplaner. Det første forslag, der var fremme, gik på ..
29
25 apr
VWS
Børsen kunne i går berette at MHI Vestas har lavet et par justering i bestyrelsen. Chef for Mitsubis..
20
24 apr
DANSKE
Idioten kan sku' vende alt omkring Danske Bank til noget negativt... 
13
23 apr
BAVA
har siddet og funderet over, om man skulle lette depotet for lidt aktier, heriblandt nogle af bavari..
13
25 apr
VWS
og når vi nu er ved bestyrelse så bør det nok også nævnes at Nordberg er blevet hyldet som årets bes..
11
24 apr
DANSKE
Tonny9 helt enig - 6212 må være nægtet et lån i DB engang. Benytter enhver lejlighed til at bagvaske..
10
24 apr
VELO
Hej Susanne   Det er ofte frustrerende, at indlæggene her på EI udarter til useriøst pjat. Hvis du v..
10
24 apr
DANSKE
Læg mærke til at når idioten opretter en ny tråd referer han altid til en eller anden artikel om Dan..
9
22 apr
MOLS
Tidligere Mols tråde: "indgående kendskab til selskabet..I bliver skuffede.."Jeg forstår ikke, hvorf..
9

OPTAKT Novo Q1 30/4: Valutamedvind udløser markant opjustering

27-04-2015 15:11:31
Novo Nordisk vil med stor sikkerhed præsentere markedet for en opjustering, når selskabet gør status for første kvartal torsdag morgen.Siden Novo kom med årsreg..

Vestas/Jyske: Forventer op til 1375 MW i Sydafrika

27-04-2015 12:08:56
Vestas er i en god position til at vinde nye ordrer i Sydafrika, lyder det i en analyse fra Jyske Bank, der fastholder sin købsanbefaling af Vestas-aktien.Sydaf..

Aktier/middag: C20 Cap balancerer på kanten af minus

27-04-2015 11:11:58
Der er ikke nogen klar retning på det danske aktiemarked mandag, hvor investorerne lader til at forholde sig afventende frem mod den byge af regnskaber, der isæ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
OPTAKT Novo Q1 30/4: Valutamedvind udløser markant opjustering
2
Vestas/Jyske: Forventer op til 1375 MW i Sydafrika
3
Svensk biotekselskab stiger med raketfart på opkøbsføler - NY2
4
Mandagens aktier: Græske toner sparker C20 Cap i rekord
5
Aktier/tendens: Positiv udsigt efter plusser i Asien og futures

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. april 2015 07:18:11
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150424.2 - EUROWEB7 - 2015-04-28 07:18:11 - 2015-04-28 07:18:11 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x